MyelinWatch EL
← Studies & programmes
Myelin repairPhase 3 study in peopleStudy stopped

RESTORE: Phase 3 study stopped before a clear answer

Published by MyelinWatch:

Study sponsor
Amsterdam UMC, location VUmc

RESTORE · The completed development study tested clemastine for an MS-related eye-movement problem, with the aim of supporting myelin repair.

What is being studied

The completed development study tested clemastine for an MS-related eye-movement problem, with the aim of supporting myelin repair.

Research stage

Phase 3 study in people

The study stopped after an early review found it was unlikely to reach its goal

What we know so far

The Phase 3 study stopped after slow enrolment and an interim review indicated it was unlikely to meet its goal. This decision alone does not prove clemastine is ineffective.

What this means for patients today

The study has stopped and is not a participation option. Its early stop is not a definitive answer about clemastine’s effects.

Treatment or approach
Clemastine • an MS-related disorder of eye movement
How it is intended to work
Uses clemastine to block certain receptors and encourage myelin-making cells to mature
Source: ClinicalTrials.gov — official clinical-trial registry ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates — newest research developments first